Skip to main content

Table 3 Percentage of different cell types in spleens of WT, PD-L1 -/- , and PD-L2 -/- male mice 96 hours after MCAO

From: PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1

A

B

Cell types (%)

Cell types (%)

Cell type

WT

PD-L1 -/-

PD-L2 -/-

Cell type

WT

PD-L1 -/-

PD-L2 -/-

 

Sham (n)

Sham (n)

Sham (n)

 

MCAO (n)

MCAO (n)

MCAO (n)

CD4

20.7 ± 3.9 (7)

21.5 ± 2.5 (9)

17.7 ± 3.1 (8)

CD4

25.4 ± 4.2 (8)b

32.8 ± 6.2 (9)a

25.0 ± 6.5 (7)a,b

CD8

8.9 ± 3.1 (7)

11.4 ± 2.3 (9)

9.4 ± 2.3 (8)

CD8

13.9 ± 6.0 (8)b

25.0 ± 8.3 (9)a

21.3 ± 5.4 (7)a

CD19

64.8 ± 7.3 (7)

60.0 ± 4.0 (9)

65.5 ± 2.9 (8)

CD19

53.7 ± 9.0 (8)b

40.3 ± 7.7 (11)a

43.2 ± 12.5 (7)a

CD11b

2.3 ± 0.9 (7)

4.4 ± 1.8 (9)

3.3 ± 0.6 (8)

CD11b

2.0 ± 0.7 (9)

3.2 ± 2.1 (9)

1.9 ± 1.5 (7)

  1. Data are presented as mean ± SEM. aValue of P ≤0.05 with respect to the strain’s sham group; bvalue of P ≤0.05 versus MCAO-induced PD-L1-/- mice. -/-, knockout; MCAO, middle cerebral artery occlusion; PD-L1, programmed death-1 ligand 1; PD-L2, programmed death-1 ligand 2; WT, wild-type.